Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IBI3016 in Japanese Participants
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Summary
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-08-01
Completion Date
2027-11-05
Last Updated
2026-09-24
Healthy Volunteers
No
Conditions
Interventions
IBI3016 Dose 4
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 3
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 2
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 1
single doses of IBI3016 administered by subcutaneous injection
Placebo
single doses of IBI3016 administered by subcutaneous injection
Locations (1)
Medical Corporation Heishinkai OPHAC Hospital
Osaka, Japan